---
title: "Pfizer accuses Metsera directors of receiving improper and extensive compensation from Novo Nordisk "
description: "Pfizer accuses Metsera directors of receiving improper and extensive compensation from Novo Nordisk for their \"misconduct.\""
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263812230.md"
published_at: "2025-10-31T21:53:10.000Z"
---

# Pfizer accuses Metsera directors of receiving improper and extensive compensation from Novo Nordisk 

> Pfizer accuses Metsera directors of receiving improper and extensive compensation from Novo Nordisk for their "misconduct."

Pfizer accuses Metsera directors of receiving improper and extensive compensation from Novo Nordisk for their "misconduct."

### Related Stocks

- [MTSR.US - Metsera](https://longbridge.com/en/quote/MTSR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo Nordisk A/S - share repurchase programme | Novo Nordisk A/S has initiated a share repurchase programme of up to DKK 15 billion, starting from 4 February 2026. As o | [Link](https://longbridge.com/en/news/276056741.md) |
| Novo Nordisk to Manufacture Wegovy in Ireland Facility | Novo Nordisk to Manufacture Wegovy in Ireland Facility | [Link](https://longbridge.com/en/news/275789396.md) |
| Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) | Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00 | [Link](https://longbridge.com/en/news/275719942.md) |
| Novo Nordisk Gets European Commission Approval for Higher-Dose Wegovy Injectable | 09:25 AM EST, 02/17/2026 (MT Newswires) -- Novo Nordisk ( NVO ) said Tuesday the European Commission has approved a 7.2  | [Link](https://longbridge.com/en/news/276138110.md) |
| EU approves higher dose of Novo's Wegovy | The European Commission has approved a higher dose of Novo Nordisk's popular weight-loss drug Wegovy, the Danish drugmak | [Link](https://longbridge.com/en/news/276134250.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.